soul trial oral semaglutide cardiovascular outcomes 2024 2025 results nejm Oral Semaglutide's Impact on Cardiovascular Events in Type 2 Diabetes Patients with Cardiovascular and Kidney Disease: SOUL Trial Results Effects of oral semaglutide on

At least one study also observed signs of ventilatory inefficiency as evidenced by an increased minute ventilation (VE)/VCO 2 slope, which itself is a poor prognostic marker in patients with heart failure [68]

Understanding Tirzepatide: What It Is: Dual GIP/GLP-1 receptor agonist First-in-class medication combining two mechanisms Activates both GIP and GLP-1 receptors Produces superior weight loss to single-agonist medications Half-life of approximately 5 days (allows once-weekly dosing) Brand Names: Zepbound: Indication: Chronic weight management in adults with obesity or overweight with comorbidities FDA Approval: November 2023 Doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg (weekly) Manufacturer: Eli Lilly Cost: $1,069/month Mounjaro: Indication: Type 2 diabetes management FDA Approval: May 2022 Doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg (weekly) Manufacturer: Eli Lilly Cost: $1,069/month Note: Identical to Zepbound, prescribed off-label for weight loss Compounded Tirzepatide: Source: FDA-registered compounding pharmacies Indication: Prescribed for weight loss by licensed providers Doses: Custom concentrations available Cost: $349-$699/month Same active ingredient as Zepbound/Mounjaro Why Tirzepatide Is More Effective: Dual Mechanism: GLP-1 Effects (Same as Semaglutide): Appetite suppression through brain receptors Slowed gastric emptying Increased insulin secretion Decreased glucagon production Additional GIP Effects: Enhanced insulin response beyond GLP-1 alone Improved insulin sensitivity in tissues Effects on fat metabolism and energy expenditure Synergistic appetite reduction Additional weight loss mechanisms Result: The combination produces 5-7% more weight loss than GLP-1 agonists alone

A Liposomal Glutathione formula is designed to protect the molecule from this process, ensuring much higher absorption

Prez-Chacn G, Astudillo AM, Ruiprez V, Balboa MA, Balsinde J (2010) Signaling role for lysophosphatidylcholine acyltransferase 3 in receptor-regulated arachidonic acid reacylation reactions in human monocytes